Description of the medicine: Pyrazidolum

PYRASIDOL (Pyrazidolum). 2, 3, 4a, 5, 6-hexahydro-8-methyl-1H-pyrazino [3,2,1-j, k] carbazole hydrochloride or 1, 10-trimethylene-8-methyl-1, 2, 3, 4-tetrahydropyrazino [1, 2a] -indole hydrochloride.

Synonyms: Pirlindole, Pirlindolum, Pirlindole.

White with a yellowish or greenish tinge crystalline powder. Almost nerastvorim in the water.

Pyrazidol is the original domestic antidepressant drug. The structure differs from other antidepressants in that it is a four-ring compound. It is an indole derivative that has elements of structural similarity with serotonin, as well as with reserpine and other condensed indole derivatives.

Pyrazidol has a pronounced antidepressant activity, and a special feature of its action is the combination of a timoleptic effect with a regulating effect on the central nervous system, expressed in the activating effect in patients with apathetic, anergic depression and sedation in patients with agitated conditions. To a certain extent, pyrazidol also has nootropic activity and improves cognitive (cognitive) functions.

In the neurochemical mechanism of the action of pyrazidol, its influence on the content and exchange in the CNS of neurotransmitter monoamines plays a major role.

This is primarily due to its inhibitory effect on MAO activity. The peculiarity of pyrazidol is a selective inhibition of MAO type A, which is short-term and completely reversible. In this way it differs significantly from the indiscriminate - irreversible - MAO inhibitors of the iproniazide group.

It should also be taken into account the different degree of pyrazidol inhibition of deamination of different monoamines. It strongly blocks the deamination of serotonin and norepinephrine and has relatively little effect on the deamination of tyramine, which creates less prerequisites for the development of the "cheese" syndrome. Pyrazidol partially inhibits the reuptake of monoamines, which brings it to a certain degree with tricyclic antidepressants. In combination, the use of pyrazidol leads to a significant activation of the processes of synaptic transmission of nervous excitation in the central nervous system.

Pharmacologically, pyrazidol is characterized by a weakening of depressive effects of reserpine, potentiating the effects of phenamine, L-dopa, 5-hydroxytryptophan. Unlike tricyclic antidepressants, pyrazidol does not have anticholinergic action.

Assign pyrazidol to patients with manic-depressive psychosis, schizophrenia with affective disorders and involuntary psychosis, which occurs with depression. The drug is indicated for depression with psychomotor retardation, as well as with depressions accompanied by anxiety-depressive and anxious-delirious components, anesthetic, hypochondriac and neurosis-like symptoms.